Charles Schwab
BNTC icon

Charles Schwab’s Benitec Biopharma BNTC Stock Holding History

Charles Schwab’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$948K Buy
70,851
+9,440
+15% +$112K ﹤0.01% 3021
2026
Q1 		$654K Buy
61,411
+16,137
+36% +$187K ﹤0.01% 3025
2025
Q4 		$610K Hold
45,274
– – ﹤0.01% 3098
2025
Q3 		$635K Hold
45,274
– – ﹤0.01% 3097
2025
Q2 		$530K Buy
+45,274
New +$633K ﹤0.01% 3119

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Charles Schwab's BNTC Position: Q2 2026 in Review

Charles Schwab increased its Benitec Biopharma (BNTC) stake by 15% in Q2 2026, buying an estimated $112K and bringing the position to 70,851 shares worth $948K. The position accounts for ﹤0.01% of the portfolio, ranked #3021.

Charles Schwab first reported a position in BNTC in Q2 2025 and has held it in 5 quarters since. 86 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Charles Schwab held 70,851 shares of Benitec Biopharma worth $948K as of Q2 2026.
  • Charles Schwab bought 9,440 Benitec Biopharma shares in Q2 2026, an estimated $112K.
  • Benitec Biopharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3021 holding.
  • Charles Schwab first reported a position in Benitec Biopharma in Q2 2025 and has held it in 5 quarters since.
  • 86 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.